Atria Wealth Solutions Inc. Buys Shares of 1,327 Insulet Co. (NASDAQ:PODD)

Atria Wealth Solutions Inc. purchased a new position in shares of Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,327 shares of the medical instruments supplier’s stock, valued at approximately $288,000.

Other institutional investors have also modified their holdings of the company. Wolff Wiese Magana LLC lifted its holdings in shares of Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 134 shares in the last quarter. Parkside Financial Bank & Trust grew its stake in shares of Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 92 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Insulet by 64.1% during the fourth quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares during the last quarter. Finally, Turtle Creek Wealth Advisors LLC acquired a new position in Insulet during the fourth quarter worth $43,000.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $190.00 to $225.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Wolfe Research raised Insulet from a “peer perform” rating to an “outperform” rating and set a $200.00 price target for the company in a research report on Tuesday. Piper Sandler lowered their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Barclays cut their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. Finally, Stifel Nicolaus boosted their target price on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Four investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $240.33.

Insider Buying and Selling

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at approximately $418,215.64. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.47% of the stock is owned by insiders.

Insulet Trading Down 4.7 %

Shares of NASDAQ:PODD opened at $175.57 on Thursday. Insulet Co. has a 12-month low of $125.82 and a 12-month high of $331.65. The business has a 50 day moving average of $170.32 and a 200-day moving average of $181.66. The company has a quick ratio of 2.62, a current ratio of 3.51 and a debt-to-equity ratio of 1.86. The stock has a market cap of $12.29 billion, a PE ratio of 60.33, a P/E/G ratio of 3.14 and a beta of 1.00.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.73. The business had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm’s quarterly revenue was up 37.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 EPS. As a group, equities research analysts forecast that Insulet Co. will post 3.08 earnings per share for the current year.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.